Aster DM Healthcare Toekomstige groei

Future criteriumcontroles 4/6

Aster DM Healthcare zal naar verwachting groeien in winst en omzet met respectievelijk 37.5% en 17.3% per jaar. De winst per aandeel zal naar verwachting groeien met 37.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 12.7% zijn.

Belangrijke informatie

37.5%

Groei van de winst

37.6%

Groei van de winst per aandeel

Healthcare winstgroei	27.2%
Inkomstengroei	17.3%
Toekomstig rendement op eigen vermogen	12.7%
Dekking van analisten	Good
Laatst bijgewerkt	25 Oct 2024

Recente toekomstige groei-updates

Earnings Beat: Aster DM Healthcare Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 12

Recent updates

Aster DM Healthcare's (NSE:ASTERDM) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Oct 31

Here's What's Concerning About Aster DM Healthcare's (NSE:ASTERDM) Returns On Capital

Oct 14

Aster DM Healthcare Limited's (NSE:ASTERDM) Popularity With Investors Is Under Threat From Overpricing

Jul 20

Capital Allocation Trends At Aster DM Healthcare (NSE:ASTERDM) Aren't Ideal

Jun 23

Aster DM Healthcare (NSE:ASTERDM) Takes On Some Risk With Its Use Of Debt

May 30

With Aster DM Healthcare Limited (NSE:ASTERDM) It Looks Like You'll Get What You Pay For

Apr 14

Aster DM Healthcare Limited (NSE:ASTERDM) Shares Could Be 39% Below Their Intrinsic Value Estimate

Mar 27

Earnings Beat: Aster DM Healthcare Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 12

Here's Why Aster DM Healthcare (NSE:ASTERDM) Can Manage Its Debt Responsibly

Feb 07

There's Been No Shortage Of Growth Recently For Aster DM Healthcare's (NSE:ASTERDM) Returns On Capital

Jan 19

Is Now An Opportune Moment To Examine Aster DM Healthcare Limited (NSE:ASTERDM)?

Apr 03

Winst- en omzetgroeiprognoses

NSEI:ASTERDM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	61,169	6,284	5,682	11,248	8
3/31/2026	51,333	4,702	4,335	8,964	8
3/31/2025	43,161	3,391	1,518	7,202	8
9/30/2024	40,166	2,261	-10,647	-4,588	N/A
6/30/2024	38,596	1,667	N/A	N/A	N/A
3/31/2024	36,989	1,224	-6,478	1,578	N/A
12/31/2023	135,049	3,241	N/A	N/A	N/A
9/30/2023	129,865	2,843	10,490	19,180	N/A
6/30/2023	124,861	3,613	N/A	N/A	N/A
3/31/2023	29,941	1,090	9,861	18,340	N/A
12/31/2022	113,984	4,804	N/A	N/A	N/A
9/30/2022	108,558	4,894	7,357	14,181	N/A
6/30/2022	105,438	5,501	N/A	N/A	N/A
3/31/2022	102,533	5,260	7,661	13,140	N/A
12/31/2021	99,164	4,051	N/A	N/A	N/A
9/30/2021	94,944	3,492	10,207	15,291	N/A
6/30/2021	92,329	2,751	N/A	N/A	N/A
3/31/2021	86,084	1,477	11,455	15,691	N/A
12/31/2020	85,886	1,735	N/A	N/A	N/A
9/30/2020	86,514	2,202	8,848	12,894	N/A
6/30/2020	84,705	1,904	N/A	N/A	N/A
3/31/2020	86,519	2,766	6,924	12,233	N/A
12/31/2019	86,382	3,548	N/A	N/A	N/A
9/30/2019	84,666	3,161	N/A	N/A	N/A
6/30/2019	82,167	3,240	N/A	N/A	N/A
3/31/2019	79,627	3,331	231	6,009	N/A
12/31/2018	75,460	3,139	N/A	N/A	N/A
9/30/2018	72,102	3,687	N/A	N/A	N/A
6/30/2018	69,394	3,582	N/A	N/A	N/A
3/31/2018	67,212	2,689	N/A	5,374	N/A
3/31/2017	59,313	1,018	N/A	3,608	N/A
3/31/2016	52,499	-590	N/A	2,027	N/A
3/31/2015	38,758	1,327	N/A	2,355	N/A
3/31/2014	28,711	1,778	N/A	3,272	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei ASTERDM ( 37.5% per jaar) ligt boven de spaarquote ( 6.7% ).

Winst versus markt: De winst van ASTERDM ( 37.5% per jaar) zal naar verwachting sneller groeien dan de Indian markt ( 17.9% per jaar).

Hoge groeiwinsten: De winst van ASTERDM zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van ASTERDM ( 17.3% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.3% per jaar).

Hoge groei-inkomsten: De omzet van ASTERDM ( 17.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ASTERDM zal naar verwachting over 3 jaar laag zijn ( 12.7 %).

Aster DM Healthcare Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 9.1% to ₹463

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 93%, revenue upgraded

Price target decreased by 7.3% to ₹453

Price target increased by 9.3% to ₹459

Earnings Beat: Aster DM Healthcare Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recent updates

Aster DM Healthcare's (NSE:ASTERDM) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Price target increased by 9.1% to ₹463

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Aster DM Healthcare Limited to Report Q2, 2025 Results on Oct 23, 2024

Here's What's Concerning About Aster DM Healthcare's (NSE:ASTERDM) Returns On Capital

Consensus EPS estimates fall by 13%

Aster DM Healthcare Appoints Mohamed Alshamari as CEO of Aster Hospitals and Clinics in Saudi Arabia

Aster DM Healthcare and Quality CARE Reportedly in Final Stages of Negotiations and Expects Deal to be Sign by the End of September 2024

Aster DM Healthcare Limited Announces Executive Changes

High number of new directors

Aster DM Healthcare Limited Approves Board Appointments

Upcoming dividend of ₹2.00 per share

Blackstone Reportedly in Talks with the Promoters of Aster DM Healthcare to Merge Quality Care India with Aster

First quarter 2025 earnings released: EPS: ₹1.49 (vs ₹0.10 in 1Q 2024)

Aster DM Healthcare Limited to Report Q1, 2025 Results on Jul 31, 2024

Aster DM Healthcare Limited's (NSE:ASTERDM) Popularity With Investors Is Under Threat From Overpricing

Capital Allocation Trends At Aster DM Healthcare (NSE:ASTERDM) Aren't Ideal

Olympus Capital Asia Investments to Sell Up to 10% Stake in Aster DM Healthcare through Block Deals

Consensus EPS estimates fall by 93%, revenue upgraded

Aster DM Healthcare Limited, Annual General Meeting, Aug 29, 2024

Price target decreased by 7.3% to ₹453

Aster Dm Healthcare Limited Proposes Final Dividend for the Financial Year 2023-24

Aster DM Healthcare (NSE:ASTERDM) Takes On Some Risk With Its Use Of Debt

Aster Dm Healthcare Limited Proposes Final Dividend for the Financial Year 2023-24

Full year 2024 earnings released: EPS: ₹2.46 (vs ₹8.54 in FY 2023)

Aster DM Healthcare Limited to Report Q4, 2024 Results on May 28, 2024

Aster DM Healthcare Limited Announces Resignation of Amitabh Johri as A Key Managerial Personnel

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 23%

Aster DM Healthcare Limited Declares Special Dividend

With Aster DM Healthcare Limited (NSE:ASTERDM) It Looks Like You'll Get What You Pay For

Aster DM Healthcare Limited Declares Special Dividend

Investor sentiment improves as stock rises 19%

Aster DM Healthcare Limited Announces Board Changes

Olympus Capital Reportedly Plans Stake Sale in Aster DM Healthcare

Aster DM Healthcare Limited (NSE:ASTERDM) Shares Could Be 39% Below Their Intrinsic Value Estimate

Price target increased by 9.3% to ₹459

Earnings Beat: Aster DM Healthcare Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

New major risk - Financial position

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Here's Why Aster DM Healthcare (NSE:ASTERDM) Can Manage Its Debt Responsibly

Aster DM Healthcare Limited to Report Q3, 2024 Results on Feb 08, 2024

There's Been No Shortage Of Growth Recently For Aster DM Healthcare's (NSE:ASTERDM) Returns On Capital

Now 20% undervalued

KKR, Ontario Teachers' Pension Plan and Care Hospitals Reportedly Submit Non-Binding Term Sheets to Acquire Stake in the Indian Business of Aster DM Healthcare

Aster DM Healthcare to Fuel India Expansion Through Buyouts

Now 20% undervalued

New minor risk - Share price stability

Consensus EPS estimates fall by 16%

Price target increased by 18% to ₹397

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: ₹0.62 loss per share (vs ₹0.93 profit in 2Q 2023)

Aster's India Unit Reportedly Draws Suitors Valuing Business At $1.5 Billion

New major risk - Financial position

Aster DM Healthcare Limited Announces Resignation Anoop Moopen as Non-Executive Director

Full year 2023 earnings: EPS misses analyst expectations

Aster DM Healthcare Limited to Report Q1, 2024 Results on Aug 14, 2023

Aster DM Healthcare Limited, Annual General Meeting, Aug 31, 2023

Aster Healthcare's Promoters Reportedly in Talks with Private Equity Groups, Look to Sell India Business

Aster DM Healthcare Confirms Talks with Fajr Capital, Others on Gulf Business

Investor sentiment improves as stock rises 16%

Consensus EPS estimates fall by 15%, revenue upgraded

Price target increased by 7.6% to ₹291

Aster Eye $300 million India Stake Sale

Full year 2023 earnings released: EPS: ₹8.54 (vs ₹10.58 in FY 2022)

Aster DM Healthcare Limited Announces Resignation of Sridar Arvamudhan Iyengar as Non-Executive Independent Director

Aster DM Healthcare Limited to Report Q4, 2023 Results on May 25, 2023

Third quarter 2023 earnings released: EPS: ₹2.80 (vs ₹2.98 in 3Q 2022)

Aster DM Healthcare Limited Appoints Rahul Kadavakolu as Group Chief Marketing Officer